NCT04624906 - Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 2, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2030

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG

Acalabrutinib

100 mg oral capsules twice daily for 1 year

DRUG

Bendamustine

90 mg/m2 on days 1 and 2 of each cycle.

DRUG

Rituximab

day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).

Trial Locations (9)

Unknown

Tom Baker Cancer Centre, Calgary

Cross Cancer Institute, Edmonton

Vancouver General Hospital, Vancouver

QEII Health Sciences Centre, Halifax

Hamilton Health Sciences Centre - Juravinksi, Hamilton

The Ottawa Hospital, Ottawa

CHU de Quebec - University Laval, Laval

McGill University Health Centre, Montreal

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto